Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting
– Findings show investigational drug reduces tics by 30%; Data presentation April 5 – Chicago, March 31, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — … Read more